LINGEGOWDA SELANERE MANGALA to Receptor, EphA2
This is a "connection" page, showing publications LINGEGOWDA SELANERE MANGALA has written about Receptor, EphA2.
Connection Strength
1.198
-
Liposomal siRNA for ovarian cancer. Methods Mol Biol. 2009; 555:29-42.
Score: 0.296
-
EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. Int J Mol Sci. 2024 Jan 20; 25(2).
Score: 0.210
-
Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. Int J Mol Sci. 2023 Feb 15; 24(4).
Score: 0.197
-
MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. Gynecol Oncol. 2021 10; 163(1):181-190.
Score: 0.177
-
EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 01; 16(9):2562-70.
Score: 0.081
-
EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009 Sep 02; 101(17):1193-205.
Score: 0.077
-
Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009 Jun; 8(11):1027-34.
Score: 0.076
-
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst. 2006 Nov 01; 98(21):1558-70.
Score: 0.064
-
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010 May 01; 70(9):3687-96.
Score: 0.020